Date: 2011-09-05

Type of information: Development agreement

Compound: EVT 302

Company: Evotec (Germany) Roche (Switzerland)

Therapeutic area: Neurodegenerative diseases

Type agreement:


Action mechanism:

Disease: Alzheimer’s disease


Evotec and Roche have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor EVT 302 in patients with Alzheimer’s disease. Roche will initiate studies in 2012 to demonstrate proof of concept and will be responsible for all clinical development, manufacturing and commercialization activities. The compound, which will be entering clinical studies in AD, was originally licensed from Roche to Evotec in 2006, and initially developed in another indication.

Financial terms:

Under the terms of the agreement, Roche will pay Evotec an upfront fee of $10 million. Evotec could receive further development and commercial milestone payments of up to $820 million as well as tiered double-digit royalties on sales.

Latest news:

Is general: Yes